Retinalamin

Retinalamin is a complex of water-soluble polypeptides isolated from the retinas of cattle, marketed as a peptide bioregulator by a Russian manufacturer ^[1]. It is administered by injection, including into the muscle and around the eye, and is used chiefly in ophthalmology within Russia and several post-Soviet countries; it is not registered as a medicine in the major Western regulatory systems ^[1]. In experimental pharmacology, the polypeptide mixture has been shown to bind several receptor targets and to distribute into the tissues of the brain and eye after injection ^[1].

The drug is used as a neuroprotective, or retinoprotective, therapy for a range of retinal disorders. Clinical studies from the region have examined it in diabetic retinopathy, where treatment was associated with favorable changes in retinal structure and electrical function on imaging and electrophysiology ^[2]. In primary open-angle glaucoma, a controlled study reported that repeated courses of retinalamin appeared to slow the structural and functional progression of the disease ^[3]. As with many peptide bioregulators, much of the supporting evidence comes from smaller studies conducted in Russia and neighboring countries ^[2][3].

The evidence base is mixed. While several clinical reports describe benefits, an experimental study in a rabbit model of light-induced retinal damage found no significant neuroprotective effect of retinalamin, illustrating that results are not uniformly positive ^[4]. Because the drug is used and studied mainly outside the major Western regulatory frameworks, it has not undergone the large international trials typical of globally marketed medicines ^[3][4].

Reported to be generally well tolerated in regional use, with allergic reactions the main concern due to its animal-tissue origin. It is typically administered by injection (intramuscular or parabulbar) by clinicians. Independent long-term safety data are limited, and it is not an approved drug in most Western countries.